Nuclear magnetic resonance-based serum metabolomic analysis reveals different disease evolution profiles between septic shock survivors and non-survivors

Table 4 Discriminatory metabolites with different variations along the H0-H24 evolution between the non-survivor group and the survivor group

Peaks	Assignment	C₁	Adj P₁	FDR₁	V₁	C₂	Adj P₂	FDR₂	V₂
2.12^m 2.32^m	Glutamate	− 0.62	0.0001	0.001	↓	0.49	0.03	0.02	↑
2.52^d 2.66^d	Citrate	− 0.59	0.0001	0.001	↓	0.59	0.002	0.004	↑
7.32^d 7.36^d	Phenylalanine	− 0.53	0.0004	0.003	↓	0.4	0.08	0.07	↑
2.07^m 2.43^m	Glutamine	− 0.49	0.001	0.01	↓	0.44	0.03	0.03	↑
1.47^d	Alanine	− 0.42	0.004	0.03	↓	0.42	0.05	0.06	↑
1.32^d 4.11^q	Lactate	− 0.62	0.0001	0.002	↓	0.2	0.26	0.21	NS
2.37^s	Pyruvate	− 0.38	0.04	0.05	↓	0.06	0.42	0.33	NS
2.03^s	Glycoprotein (N-acetyl)	0.26	0.08	0.09	NS	− 0.48	0.01	0.01	↓
3.02^s	Creatinine	− 0.21	0.15	0.13	NS	0.47	0.02	0.03	↑

C₁, correlation of the metabolite to the discriminatory model for the survivors; C₂, correlation of the metabolite to the discriminatory model for the non-survivors. For each listed metabolite, the sign of C₁ is opposite to that of C₂; Adj P₁, adjusted P value (with Bonferroni correction) of the metabolite in the comparison between H0 and H24 samples for the survivors; Adj P₂, adjusted P value of the metabolite in the comparison between H0 and H24 samples for the non-survivors; FDR₁, false discovery rate for the P value calculated with the survivors; FDR₂, false discovery rate for the P value calculated with the non-survivors; V₁, variation in concentration for the metabolites from H0 to H24 for the survivors; V₂, variation in concentration for the metabolites from H0 to H24 for the non-survivors; ↑, increased concentration of the metabolite at H24 compared with H0; ↓, decreased concentration of the metabolite at H24 compared with H0. NS, non-significant (Adj P > 0.05) variation

ISSN: 1364-8535